Multivitamin for injection 13 is a compound vitamin preparation containing both 9 water-soluble vitamins and 4 fat-soluble vitamins which is used clinically for the prevention of vitamin deficiency in adults receiving parenteral nutrition and children over 11 years of age. Compared to Multivitamin for injection 12 vitamin K has been added for regulating coagulation maintaining bone health and other aspects in parenteral nutrition. Multivitamin for injection 13 was first marketed in the United States in 2003. However it has been marketed in China in late 2020 so domestic clinicians might have little experience with the injection. In 2015 Chinese Society of Parenteral and Enteral Nutrition issued Expert Consensus on Clinical Application of Vitamin Preparations which provided recommendations on vitamin supplementation in various clinical scenarios as well as the use of common clinical preparations of vitamins. In recent years many new advances have been made in the clinical application of vitamins. Therefore in order to promote the standardized use of Multivitamin for injection 13 by Chinese physicians improve the understanding of the assessment of patients' vitamin metabolism and enhance the understanding of vitamin deficiency and further promote the development of research on multivitamins injections in China Chinese Society of Nutritional Oncology CSNO established the evaluation methods and contents of various indicators according to the current situation of nutritional diagnosis and treatment in China and evidence-based medical evidence published at home and abroad. Based on the 2015 Expert Consensus on Clinical Application of Vitamin Preparations and relevant international guidelines CSNO formed 15 recommendations through the expert consensus method involving the necessity comprehensiveness clinical application of Multivitamin for injection 13 and detection and monitoring of vitamins.